Mostrar el registro sencillo del ítem
dc.contributor.author
Labrada, Mayrel
dc.contributor.author
Clavell, Marilyn
dc.contributor.author
Bebelagua, Yanín
dc.contributor.author
De León, Joel
dc.contributor.author
Alonso, Daniel Fernando
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Gabri, Mariano Rolando
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Veloso, Roberto C
dc.contributor.author
Vérez, Vicente
dc.contributor.author
Fernández, Luis E.
dc.date.available
2020-04-15T17:10:01Z
dc.date.issued
2009-12
dc.identifier.citation
Labrada, Mayrel; Clavell, Marilyn; Bebelagua, Yanín; De León, Joel; Alonso, Daniel Fernando; et al.; Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy; Informa Healthcare; Expert Opinion on Biological Therapy; 10; 2; 12-2009; 153-162
dc.identifier.issn
1471-2598
dc.identifier.uri
http://hdl.handle.net/11336/102631
dc.description.abstract
OBJECTIVE: The target concept means not only an aberrant expression of a particular molecule in tumour tissues but also evidence of a clear therapeutic advantage, as a consequence of immune-intervention, in an antigen-positive relevant tumour model. Since we reported the presence of NGcGM3 ganglioside in human breast tumours years ago and though Phase I clinical trials of a ganglioside containing vaccine have been conducted, a definitive direct validation of this peculiar molecule as target for cancer immunotherapy has remained unperformed. METHODS: Two animal models were used: leghorn chickens and C57BL/6 mice. The murine 3LL-D122 cell line, the derived subcutaneous tumours and metastatic lung lesions were processed for gangliosides identification. Active immunotherapy experiments in the 3LL-D122 spontaneous lung metastasis model were performed with NGcGM3/VSSP vaccine prepared by conjugation of NGcGM3 with the outer membrane proteins of Neisseria meningitides. RESULTS: The 3LL-D122 Lewis lung carcinoma results were consistent with an increased expression of NGcGM3 from primary tumours to metastatic lesions, as observed in human breast cancer samples. Both vaccines, prepared with synthetic or natural-source-derived ganglioside, showed similar anti-tumour and immunogenicity profiles. Finally, a clear involvement of NK1.1(+) cells and CD8(+) T cells in the anti-metastatic effect elicited by the vaccine was manifested. CONCLUSIONS: While 'proof of concept' Phase II and III clinical trials with the NGcGM3/VSSP vaccine in cancer patients are currently ongoing these results reasonably sustain the validation of this peculiar ganglioside as a novel target for cancer immunotherapy.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Informa Healthcare
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Ganglioside
dc.subject
Immunotherapy
dc.subject
Cancer
dc.subject
Target
dc.subject.classification
Bioquímica y Biología Molecular
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Básica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2020-03-04T17:31:41Z
dc.journal.volume
10
dc.journal.number
2
dc.journal.pagination
153-162
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Londres
dc.description.fil
Fil: Labrada, Mayrel. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Clavell, Marilyn. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Bebelagua, Yanín. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: De León, Joel. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Alonso, Daniel Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Gabri, Mariano Rolando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina
dc.description.fil
Fil: Veloso, Roberto C. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Vérez, Vicente. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Fernández, Luis E.. Center of Molecular Immunology; Cuba
dc.journal.title
Expert Opinion on Biological Therapy
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/14712590903443084
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1517/14712590903443084
Archivos asociados